STOCK TITAN

Cassava Sciences Inc - SAVA STOCK NEWS

Welcome to our dedicated news page for Cassava Sciences (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cassava Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cassava Sciences's position in the market.

Rhea-AI Summary
Cassava Sciences completes patient enrollment in Phase 3 trials for oral simufilam in Alzheimer's disease dementia. Top-line results for 52-week trial expected by year-end 2024, and 76-week trial expected by mid-year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
-
Rhea-AI Summary
Cassava Sciences announces a potentially significant safety finding based on MRI brain data from Alzheimer's patients in a Phase 3 clinical trial of simufilam. The data suggests that simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities (ARIA), unlike other drugs in the same class. The new safety finding is based on an independent evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer's patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.8%
Tags
none
-
Rhea-AI Summary
Cassava Sciences responds to leaked CUNY report on research misconduct allegations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.28%
Tags
none
Rhea-AI Summary
Cassava Sciences CEO to present at Jefferies Biotech CNS/Neuro Summit on October 11th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
conferences
-
Rhea-AI Summary
Cassava Sciences completes enrollment of 804 Alzheimer's patients in Phase 3 clinical trial for simufilam, with a second trial expected to enroll approximately 1,100 patients by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary
An Independent Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences' Phase 3 studies of simufilam continue as planned, without modification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
Rhea-AI Summary
New research confirms the biological activity of simufilam in Alzheimer's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Cassava Sciences invited to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.95%
Tags
none
Cassava Sciences Inc

Nasdaq:SAVA

SAVA Rankings

SAVA Stock Data

983.84M
40.20M
7.17%
32.7%
27.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About SAVA

refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.